Brief: Strides Pharma Science Says Stelis Biopharma's CDMO Partner Gets Approval For Key ANDA From USFDA
Dec 28 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* STRIDES PHARMA SCIENCE LTD - STELIS BIOPHARMA'S CDMO PARTNER RECEIVES APPROVAL FOR A KEY
ANDA
FROM USFDA
Source text for Eikon: ID:nBSE2VgM12
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees